Human Vaccines & Immunotherapeutics最新文献_第8页

Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China. HepE Hecolin®在临床稳定期慢性乙型肝炎患者中的免疫原性和安全性：中国的一项开放标签研究

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-10 DOI: 10.1080/21645515.2024.2448882

Li Zhang, Qiufen Zhang, Jiaye Liu, Wenlong Wu, Zechun Jiang, Bingyu Yan, Qingfan Cao, Haidong Liu, Huirong Pan, Jingjing Lv, Yi Feng, Fujie Xu, Shoujie Huang, Aiqiang Xu

{"title":"Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.","authors":"Li Zhang, Qiufen Zhang, Jiaye Liu, Wenlong Wu, Zechun Jiang, Bingyu Yan, Qingfan Cao, Haidong Liu, Huirong Pan, Jingjing Lv, Yi Feng, Fujie Xu, Shoujie Huang, Aiqiang Xu","doi":"10.1080/21645515.2024.2448882","DOIUrl":"10.1080/21645515.2024.2448882","url":null,"abstract":"Acute hepatitis E infection could induce severe outcomes among chronic hepatitis B (CHB) patients. Between 2016 and 2017, an open-label study was conducted to evaluate the immunogenicity and safety of hepatitis E vaccine (HepE) in CHB patients, using healthy adults as parallel controls in China. Eligible participants who were aged ≥30 y were enrolled in the study. The CHB group included participants who had ever developed symptoms of hepatitis because of CHB but was currently at a clinically stable stage, which was defined as ALT ≤ 1.5 times of upper limit of the normal range (ULN) in this study. The control group included healthy adults who had hepatitis B surface antigen (HBsAg) negative. HepE was administered for 0, 1, 6 months for all participants. At 1 month after the third-dose vaccination (month 7), the seroconversion rates of anti-HEV IgG were >97% in both groups. The geometric mean concentration (GMC) of anti-HEV IgG in the CHB group was non-inferior to the healthy adult group (0.69 WU/mL, 95% CI 0.55-0.85). The proportion of the participants with adverse events ≥ grade 3 was similar in both groups (p = .99), and no vaccine-associated severe adverse events were identified. Changes in the liver function indicators were not of clinical significance. The HepE was highly immunogenic and well tolerated among clinically stable CHB patients and healthy adults.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2448882"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global research trends on biomarkers for cancer immunotherapy: Visualization and bibliometric analysis. 癌症免疫治疗生物标志物的全球研究趋势：可视化和文献计量分析。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-08 DOI: 10.1080/21645515.2024.2435598

Yuan Qiao, Dong Xie, Zhengxiang Li, Shaohua Cao, Dong Zhao

{"title":"Global research trends on biomarkers for cancer immunotherapy: Visualization and bibliometric analysis.","authors":"Yuan Qiao, Dong Xie, Zhengxiang Li, Shaohua Cao, Dong Zhao","doi":"10.1080/21645515.2024.2435598","DOIUrl":"10.1080/21645515.2024.2435598","url":null,"abstract":"The global burden of cancer continues to grow, posing a significant public health challenge. Although cancer immunotherapy has shown significant efficacy, the response rate is not high. Therefore, the objective of our research was to identify the latest research trends and hotspots on biomarkers from 1993 to 2023. Data were collected from the database Web of Science core collection. Bibliometric analysis and visualization were conducted with CiteSpace(6.3.1), VOSviewer (v1.6.20), R-bibliometrix(v4.3.3), and Microsoft Excel(2019). A total of 2686 literatures were retrieved. The sheer annual volume of publications has shown a rapid upward trend since 2015. The United States has generated the most publications and Harvard University ranked as a leading institution. The global biomarker research on immune checkpoint inhibitors (ICIs) revealed regional differences and in-depth explorations should be promoted in developing countries. Although China has become the second largest country in terms of publication, the average citation per paper and the total link strength were both lower than the other countries. The research on biomarkers mainly concentrated upon the following aspects: PD-1/PD-L1, CTLA-4, gene expression, adverse events, total mutational burden (TMB), body mass index (BMI), gut microbiota, cd8(+)/cd4(+) t-cells, and blood-related biomarkers such as lactate dehydrogenase (LDH), neutrophil-lymphocyte ratio (NLR), cytokines. Furthermore, \"artificial intelligence\" and \"machine learning\" have become the most important research hotspot over the last 2 y, which will help us to identify useful biomarkers from complex big data and provide a basis for precise medicine for malignant tumors.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2435598"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hospital burden of pneumococcal disease in Spain (2016-2022): A retrospective study. 西班牙肺炎球菌病医院负担（2016-2022）：一项回顾性研究

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-09 DOI: 10.1080/21645515.2024.2437915

Ruth Gil-Prieto, Valentín Hernandez-Barrera, Patricia Marín-García, Alba González-Escalada, Ángel Gil-de-Miguel

{"title":"Hospital burden of pneumococcal disease in Spain (2016-2022): A retrospective study.","authors":"Ruth Gil-Prieto, Valentín Hernandez-Barrera, Patricia Marín-García, Alba González-Escalada, Ángel Gil-de-Miguel","doi":"10.1080/21645515.2024.2437915","DOIUrl":"10.1080/21645515.2024.2437915","url":null,"abstract":"Pneumococcal disease is a leading cause of morbidity and mortality worldwide. From 2016 to 2022, 358,603 hospitalized patients were identified as having pneumococcal disease. The overall annual hospitalization rate was 108.9 hospitalizations per 100,000 people, which significantly increased with age, reaching 748.0 hospitalizations per 100,000 among those aged ≥90 years. The hospitalization rates for pneumococcal pneumonia, meningitis, and sepsis were 25.4, 0.7, and 3.5 hospitalizations per 100,000 people, respectively, reaching the highest rates in those ≥90 years of age for pneumococcal pneumonia and sepsis, with 241.6 and 22.0 hospitalizations per 100,000 people, respectively, and in those <1 year of age for meningitis, with 3.4 hospitalizations per 100,000 people. The total number of deaths among all hospitalized pneumococcal infection patients was 51,668, with a total case fatality rate of 14.4%. The case fatality rates for pneumococcal pneumonia, meningitis, and sepsis were 7.9%, 10.6%, and 19.8%, respectively. The case fatality rate increased dramatically with age. Most patients presented with at least one underlying condition. The case fatality rate among patients with at least one comorbidity was significantly higher (p < .05) than that among patients without underlying conditions (16.0% vs. 3.2%, respectively), with a fivefold greater probability of death (OR = 5.7). During this period, the annual cost of hospitalizations for the health system exceeded EUR 383 million. Thus, the use of new broad-spectrum PCVs and improved vaccination protocols for elderly individuals and people with comorbidities could help reduce the high hospital burden of disease and mortality due to pneumococcal infection in our country.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2437915"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preferences for and drivers of adult vaccination clinic site selection: A cross-sectional study in 30 provinces in China. 成人疫苗接种诊所选址的偏好和驱动因素：中国30个省份的横断面研究

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-10 DOI: 10.1080/21645515.2024.2442104

Yuxi Liu, Yanlin Cao, Yugang Li, Siyuan Liu, Yunshao Xu, Weizhong Yang, Luzhao Feng

{"title":"Preferences for and drivers of adult vaccination clinic site selection: A cross-sectional study in 30 provinces in China.","authors":"Yuxi Liu, Yanlin Cao, Yugang Li, Siyuan Liu, Yunshao Xu, Weizhong Yang, Luzhao Feng","doi":"10.1080/21645515.2024.2442104","DOIUrl":"10.1080/21645515.2024.2442104","url":null,"abstract":"Focusing on vaccines available to adults and not in the immunization schedule, this study investigates the preferences and factors influencing adults in selecting vaccination clinic locations. It aims to provide strategic insights for boosting vaccination rates by analyzing adults' decision-making factors. This contributes to developing more efficient, patient-focused vaccination strategies that tackle vaccine hesitancy and improve access to vaccination sites. We conducted a cross-sectional study through the \"YueMiao\" platform from November 1 to December 10, 2023, using convenience and purposive sampling to engage 2014 participants. We collected data via online surveys that included questions about sociodemographic characteristics, sources of vaccination clinic information, clinic satisfaction, and the impact of site selection on vaccination decisions. Our findings reveal that adults' site preferences for vaccination are influenced by gender, age, income, and vaccination history. Participants showed a strong preference for locations that offer convenience, efficiency, transparent pricing, and a comfortable environment. Analysis of service satisfaction at these clinics indicates that vaccinated individuals report higher satisfaction with appointment systems, wait times, and service hours than those unvaccinated. Furthermore, the preference for vaccination sites consistently aligns with the vaccine type, with a majority opting for community health service centers. Our results suggest that public health strategies should concentrate on enhancing site convenience, service quality, and information transparency to elevate adult vaccination rates. Future initiatives should aim to increase public trust in vaccines, improve the selection and quality of vaccination sites, and effectively utilize digital technology for spreading vaccination information.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2442104"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current status of immunisation for herpes zoster. 带状疱疹的免疫现状。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-06 DOI: 10.1080/21645515.2024.2445384

Anthony Lawrence Cunningham, Kerrie Jane Sandgren, Janette Taylor

引用次数: 0

Hemostatic changes following COVID-19 vaccination: Do they promote a pro-thrombotic state? COVID-19疫苗接种后的止血变化：它们是否促进了促血栓状态？

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2024-12-19 DOI: 10.1080/21645515.2024.2439627

Tarinee Rungjirajittranon, Yupa Nakkinkun, Bundarika Suwanawiboon, Yingyong Chinthammitr, Weerapat Owattanapanich, Theera Ruchutrakool

引用次数: 0

The significance of antibody to hepatitis B surface antigen in infection and clearance of hepatitis B virus. 乙型肝炎表面抗原抗体在乙型肝炎病毒感染和清除中的意义。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-03 DOI: 10.1080/21645515.2024.2445283

Ling Ding, Jiaquan Huang, Shuaiwen Huang

引用次数: 0

Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies. 制定和验证牛津疫苗技术评价基准量表（OBSRVT），这是一种评估公众对下一代疫苗输送技术态度的量表。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-03 DOI: 10.1080/21645515.2025.2469994

Jonathan Kantor, Robert C Carlisle, Samantha Vanderslott, Andrew J Pollard, Michael Morrison

{"title":"Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies.","authors":"Jonathan Kantor, Robert C Carlisle, Samantha Vanderslott, Andrew J Pollard, Michael Morrison","doi":"10.1080/21645515.2025.2469994","DOIUrl":"10.1080/21645515.2025.2469994","url":null,"abstract":"Next-generation vaccine delivery technologies may provide significant gains from both a technical and behavioral standpoint, but no scale has yet been developed to assess public attitudes to novel vaccine delivery technologies. We therefore performed a cross-sectional validation study that included 1,001 demographically representative participants from the UK and US to develop and validate a novel scale, the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT). A sample of 500 UK participants was used to perform exploratory factor analysis with categorical variables (using a polychoric correlation matrix) followed by promax oblique factor rotation to develop the initial model. This yielded a 15-item 4-domain scale with domains including acceptance (6 items), effectiveness (4 items), comfort (3 items), and convenience (2 items). This model was tested for robustness on a 501-participant demographically representative sample from the US. A confirmatory factor analysis with a Satorra-Bentler scaled test statistic was performed, which demonstrated adequate goodness of fit statistics including the root mean squared error of approximation (0.057), standardized root mean squared residual (0.053), and comparative fit index (0.938). Reliability as internal consistency was excellent (alpha = 0.92). Convergent validity with the Oxford Needle Experience Scale was supported by an adequate correlation (r = 0.31, p < .0001), while discriminant validity was supported by a lack of correlation with an unrelated question (r = -0.03, p < .0001). These findings suggest that the OBSRVT scale represents a feasible, valid, and reliable scale that could be used to gauge the acceptability of existing and future vaccine delivery technologies, and further investigation and testing should be considered.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2469994"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors associated with CIN2-3 recurrence: A single center retrospective analysis. 与CIN2-3复发相关的因素：单中心回顾性分析。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-21 DOI: 10.1080/21645515.2025.2469410

Zhuo-Yi Li, Kai Wang, Xiao-Ling Shen, Qing Li

{"title":"Factors associated with CIN2-3 recurrence: A single center retrospective analysis.","authors":"Zhuo-Yi Li, Kai Wang, Xiao-Ling Shen, Qing Li","doi":"10.1080/21645515.2025.2469410","DOIUrl":"10.1080/21645515.2025.2469410","url":null,"abstract":"Cervical intraepithelial neoplasia, grade 2-3 (CIN2-3), classified as histologic high-grade squamous intraepithelial lesion (HSIL), is associated with a higher recurrence rate and an increased risk of developing cervical cancer. The predictive and influencing factors for CIN2+ relapse are still uncertain and controversial. This study aims to further clarify the risk factors of CIN 2-3 recurrence. The retrospective cohort study enrolled 142 patients with CIN 2-3, aged between 20 to 60 years, all of whom received treatments to remove the lesions. All patients were followed for at least two years to assess outcomes. The primary outcome indicators were high-risk HPV (HR-HPV) status and cervical lesions status within two years after treatment. Fisher's exact test or Pearson's chi-squared test and the Kruskal-Wallis (K-W/H) test were used for univariate analysis. Logistic regression analysis was applied to identify independent risk factors, and the results were presented using a forest plot. The study found no significant differences in basic characteristics and HR-HPV status, except for parity (p = .020). HPV genotype before treatment and margin status were significantly associated with cervical lesion status after treatment, with P-values of 0.003 and 0.031, respectively. Cytology before treatment and HPV vaccination were independent factors influencing cervical lesions status two years after treatment, with odds ratios (OR) of 0.634 (95% CI: 0.443-0.908) and 0.340 (95% CI: 0.121-0.952), respectively. This study is the first to report independent factors influencing CIN 2-3 recurrence and underscores the importance of considering adjuvant HPV vaccination for women with cervical preinvasive disease.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2469410"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary and methodological insights: Reaching girls/women, boys/men and vulnerable groups to maximise uptake for the Human papillomavirus vaccine. 评论和方法见解：覆盖女孩/妇女、男孩/男子和弱势群体，最大限度地吸收人乳头瘤病毒疫苗。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-18 DOI: 10.1080/21645515.2025.2478705

Carol Gray Brunton, Janette Pow, Elaine Carnegie, Dafina Petrova, Rocio Garcia Retamero, Anne Whittaker, Irina Todorova

{"title":"Commentary and methodological insights: Reaching girls/women, boys/men and vulnerable groups to maximise uptake for the Human papillomavirus vaccine.","authors":"Carol Gray Brunton, Janette Pow, Elaine Carnegie, Dafina Petrova, Rocio Garcia Retamero, Anne Whittaker, Irina Todorova","doi":"10.1080/21645515.2025.2478705","DOIUrl":"https://doi.org/10.1080/21645515.2025.2478705","url":null,"abstract":"The human papillomavirus (HPV) vaccine has been shown to be an effective cancer-prevention vaccine against oncogenic types of the HPV virus implicated in cervical, anogenital, and oropharyngeal cancers. Since Covid-19, there are global suboptimal uptake rates for the HPV vaccine. In high-income countries, there are persistently lower uptake rates among boys/men and vulnerable groups despite many countries now offering the HPV vaccine to both girls and boys in gender-neutral vaccine campaigns. It is important to understand the nuances with vaccine hesitancy and qualitative research approaches can be valuable to understand rich, contextual understandings in public health communication among hard-to-reach groups. This commentary draws insights from previous literature and our own research including two studies submitted to this Special Edition on Vaccine Communication. We consider the cultural context, gender and specific hard-to-reach groups in Scotland including those with an intellectual disability, sexual minorities, and ethnically diverse groups to draw some insights. Such groups may experience taboos and stigma in various guises. It is important that public health communication in given contexts is gender-inclusive and can incorporate messages that reach vulnerable groups. Cancer prevention communication delivered by trusted healthcare providers and community leaders are important strategies to deliver trusted messages.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2478705"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0